Godavari Biorefineries Limited · NSE:GODAVARIB
Godavari Biorefineries — Q1 FY26 Earnings Presentation
20 slides from Godavari Biorefineries's earnings presentation
Slide 1: Godavari Biorefineries Limited Investor Presentation Q1 FY26
Godavari Biorefineries Limited Investor Presentation| Q1 FY26
Slide 2: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Godavari Biorefineries Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for an
Slide 3: Q1 FY26 Performance
Q1 FY26 Performance GROUP
Slide 4: Industry Updates
Industry Updates The global chemicals industry is seeing renewed momentum as companies accelerate the shift from fossil-based to bio-based chemicals. Bio-based Chemicals Gain Global players are actively collaborating to co-develop and create sustainable chemical solutions as part of the ongoing tran
Slide 5: Key Revenue & EBITDA Growth Drivers
Key Revenue & EBITDA Growth Drivers Global - Transition to Green Chemistry India- Green Energy Transition Bio-Based Chemicals Ethanol Increase Bio-Based Specialty Chemicals Business Increase Capacity and Capacity Utilization Increase proportion of Specialty Chemicals in portfolio Diversify feedstock
Slide 6: Business Updates
Business Updates Accelerating Growth with Operational Excellence and Strategic Investments Bio-based Specialty Chemicals Expanding Ethanol Capacity • Our 200 KLPD fungible Grain/Maize distillery is progressing ahead of schedule. Focus on expanding capacity and implementing • Will add 60 Mn liters Et
Slide 7: Novel Anti-Cancer molecule
Novel Anti-Cancer molecule Drug Discovery for Triple-Negative Breast Cancer (Promising preclinical efficacy in breast and prostate cancer) R&D Milestone- Drug Discovery efforts Patent Update Safety Trials Science ❑ European patent for our novel anti- cancer molecule has been validated in Spain, the
Slide 8: Road to Drug Discovery
Road to Drug Discovery Milestones 1 Pre-clinical trials 2 Safety trials 3 Mechanism of action 4 Preliminary Efficacy trials 5 Out-licensing of molecule 8
Slide 9: Q1 FY26 Performance Highlights (Y-o-Y Basis)
Q1 FY26 Performance Highlights (Y-o-Y Basis) (Consolidated) Total Income EBITDA PAT Rs. 534.0 Crs Rs. 6.5 Crs Rs. (16.0) Crs + 2% YoY Margin 1.2% Margin (3%) Finance Cost (Rs. Crs) EBITDA (Rs. Crs) PBT (Rs. Crs) 6.5 -22.3 -41.6 19.6 15.3 -9.5 Q1 FY25 Q1 FY26 Q1 FY25 Q1 FY26 Q1 FY25 Q1 FY26 ₹240 cror
Slide 10: Q1 FY26 Performance Highlights (Y-o-Y Basis)
Q1 FY26 Performance Highlights (Y-o-Y Basis) (Consolidated) Q1 FY25 Revenue-Mix * Q1 FY26 Revenue-Mix * 1% 2% 26% 33% 39% 45% Q1FY26 Q1FY25 28% 26% Sugar & Cogen Chemical Ethanol Unallocated Revenue from Bio-based chemicals & Ethanol increased to 65% in Q1FY26 compared to 54% in Q1FY25 10 *Some of t
Slide 11: Segmental Highlights-Bio-based Chemicals
Segmental Highlights-Bio-based Chemicals (Consolidated) Revenue (Rs. Crs) Q1 FY25 Q1 FY26 YoY Growth 146.0 141.2 (3%) Accelerating Growth Through Specialty Chemicals Revenue Break-up EBITDA (Rs. Crs) 48% 39% 12.5 52% 61% 8.7 Q1 FY25 Q1 FY26 Q1 FY25 Q1 FY26 Ethyl Acetate Bio Based Specialty Chemicals
Slide 12: Segmental Highlights-Ethanol
Segmental Highlights-Ethanol (Consolidated) Revenue (Rs. Crs) Q1 FY25 Q1 FY26 YoY Growth 136.4 205.4 51% Gaining Traction in Ethanol Business Revenue (Rs. Crs) EBITDA (Rs. Crs) 205.4 13.1 11.5 136.4 Q1 FY25 Q1 FY26 Q1 FY25 Q1 FY26 B-heavy molasses-based Ethanol back in play after prolonged pause, po
Slide 13: Segmental Highlights- Sugar & Co-Generation
Segmental Highlights- Sugar & Co-Generation (Consolidated) Revenue (Rs. Crs) Q1 FY25 Q1 FY26 YoY Growth 234.4 177.5 (24%) Revenue Break-up (%) EBITDA (Rs. Crs) 72% 84% -17.6 -28.6 14% 9% 8% 1% 6% 6% Q1 FY25 Q1 FY26 Q1 FY25 Q1 FY26 Non Branded Sugar Branded Sugar Co-generation Others 13
Slide 14: Consolidated Profit & Loss Statement – Q1 FY26
Consolidated Profit & Loss Statement – Q1 FY26 Particulars (in INR Cr) Q1 FY26 Q1 FY25 Q4 FY25 FY25 Revenue from Operations 533.2 522.5 579.5 1,870.3 Other Income 0.7 2.7 9.3 16.7 Total Income 534.0 525.3 588.8 1,886.9 Cost of Materials Consumed 205.5 128.3 575.3 1,242.8 Purchase of Finished Goods 8
Slide 15: FY29 Outlook: Strategic Levers for Value Creation
FY29 Outlook: Strategic Levers for Value Creation Unlocking 3X EBITDA by FY29 from FY25 Divisions Bio Based Chemicals Ethanol • Increase Bio-Based Specialty Chemicals Business • Increase Capacity and Capacity Utilization Drivers • Increase proportion of Specialty Chemicals in portfolio • Diversify f
Slide 16: Growth in Bio Based Chemicals & Ethanol
Growth in Bio Based Chemicals & Ethanol Bio Based Chemicals Ethanol Major growth in the revenue from Bio-based Major growth in the revenue from Ethanol Chemicals business would reflect in FY27,FY28 business would reflect in FY26,FY27 and FY28 and FY29 Sugar & Cogeneration Drug Discovery Molecule The
Slide 17: Company Overview
Godavari Biorefineries Ltd \ Company Overview GROUP
Slide 18: Integrated Bio-refinery across value chain: Sugar, Ethanol, Bio-Chemicals, Power & Others
Integrated Bio-refinery across value chain: Sugar, Ethanol, Bio-Chemicals, Power & Others… Planned Products GRAIN BASED ETHANOL SPECIALTY CHEMICALS Current Products BHUMILABH FARM INPUTS (BIO-FERTILAZERS) SUGARCANE WAX BIOGAS PRESSMUD SUGARCANE BEVERAGE SUGAR FARM MOLASSES JUICE BAGASSE ELECTRICITY
Slide 19: Board of Directors
Board of Directors Promoter has played a significant role in the development and growth of the company... Shri Samir Shantilal Somaiya (Chairman & Managing Director) • Conferred with the ‘ Knight of the Order of the Star of Italy’ • Conferred with ‘Lala Shriram National Award for Leadership in the C
Slide 20: Thank You
Thank You Godavari Biorefineries Ltd CIN: L67120MH1956PLC009707 Name – Mr. Ashish Sinha Title – AGM- IR & Finance investorrelations@somaiya.com Email – investorrelations@somaiya.com Ms. Prachi Ambre Mr. Irfan Raeen +91 83559 85370 Prachi.ambre@in.mpms.mufg.com +91 97737 78669 Prachi.ambre@in.mpms.mu
Godavari Biorefineries — Q1 FY26 Earnings Presentation on 6ix